Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28188340 | 0.84 | NOTUM (0.63) | NOTUMKMT2ATP53MEN1USP2 | |
| SCHEMBL4687156 | 0.83 | KMT2A (0.57) | NOTUMKMT2ATP53MEN1USP2 | |
| SCHEMBL4202843 | 0.82 | TP53 (0.61) | NOTUMKMT2ATP53NPC1RAB9A | |
| SCHEMBL4212154 | 0.82 | MAPT (0.57) | NOTUMKMT2ALMNA | |
| SCHEMBL21152328 | 0.79 | NOTUM (0.72) | NOTUMKMT2ATP53MEN1LMNA | |
| SCHEMBL4210419 | 0.78 | KMT2A (0.62) | NOTUMKMT2ATP53MEN1USP2 | |
| SCHEMBL4211625 | 0.78 | USP2 (0.62) | NOTUMKMT2ATP53MEN1USP2 | |
| SCHEMBL19397284 | 0.78 | NOTUM (0.71) | NOTUMKMT2ATP53MEN1LMNA | |
| SCHEMBL27922888 | 0.78 | KMT2A (0.65) | NOTUMKMT2ATP53MEN1USP2 | |
| SCHEMBL4203269 | 0.76 | TP53 (0.54) | NOTUMKMT2ATP53USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579480-B2 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2009-08-25 | — | — | US | disclosed |
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | TOYO KASEI KOGYO COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| EP-1650198-A1 | ALKOXYTETRAZOL-1-YLBENZALDEHYDE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Toyo Kasei Kogyo Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060630-A1 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same | ALDH7A1, NAT1, ARSA | NOTUM 1223/4885KMT2A 303/4885TP53 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.